• Flumequine: DNA Topoisomerase II Inhibitor for Advanced Assa

  2026-05-15

  Flumequine, a potent DNA topoisomerase II inhibitor from APExBIO, empowers researchers with reproducible, high-fidelity tools for dissecting DNA replication and drug response in cancer and antibiotic resistance studies. Its unique solubility and inhibition profile streamline protocol design and troubleshooting in next-generation in vitro assays.

• WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc

  2026-05-14

  This study uncovers the central role of the WNT5a/GSK3/β-catenin pathway in controlling adipogenic differentiation of skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological, cytometric, and transcriptomic methods, it demonstrates that modulating this axis can limit fat infiltration in muscle, offering a new direction for therapeutic strategies in myopathies.

• MLN2238 (SKU A4008): Reliable Proteasome β5 Subunit Inhibiti

  2026-05-14

  This article addresses practical laboratory challenges in cell viability, proliferation, and cytotoxicity assays, highlighting how MLN2238 (SKU A4008) from APExBIO offers reproducible, quantitative solutions. Through scenario-driven Q&A, it demonstrates MLN2238's value as a potent, reversible proteasome β5 subunit inhibitor for oncology research, especially in settings requiring precise inhibition and robust data. Researchers are guided on protocol optimization, data interpretation, and vendor selection, with evidence-based links and actionable recommendations.

• M344: Precision Tool for Epigenetic Modulation in Oncology R

  2026-05-13

  Explore the unique capabilities of M344, a potent histone deacetylase inhibitor, in driving targeted epigenetic modulation for cancer and HIV latency research. This article provides advanced scientific analysis, protocol guidance, and practical insights distinct from current literature.

• PLGA Nano-Adjuvant Enhances Chick Mucosal and Systemic Immun

  2026-05-13

  This study introduces a novel PLGA-based nano-adjuvant encapsulating Lagenaria siceraria polysaccharide and retinoic acid, demonstrating improved mucosal and systemic immune responses against H9N2 avian influenza in chicks. The findings highlight sustained antigen release, targeted intestinal delivery, and robust IgA production, with significant implications for advancing vaccine adjuvant technology.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-12

  Schwartz’s dissertation advances in vitro drug evaluation by separating and quantifying drug-induced growth inhibition and cell death in cancer models, highlighting the distinct and overlapping effects of anti-cancer agents. This methodological refinement allows for more accurate assessment of candidate therapies, impacting the selection and optimization of agents such as Tivozanib (AV-951) in oncology research.

• Latrunculin A: Reversible Inhibitor of Actin Assembly in Res

  2026-05-12

  Latrunculin A is a precision tool enabling rapid, reversible actin cytoskeleton disruption for advanced cell biology and virology studies. Its proven efficacy in cytoskeletal disaggregation and viral pathogenesis models—now including the actin–myosin II network in DEV infection—differentiates it as an essential reagent for dissecting complex cellular dynamics.

• Biomimetic Nanoparticles Target Ovarian Inflammation via Nrf

  2026-05-11

  This study introduces a dual-targeted nanoparticle system that efficiently delivers α-cyperone to granulosa cells, alleviating LPS-induced inflammation by activating the Nrf2/HO-1 pathway and suppressing ROS. The findings provide a mechanistically supported strategy for mitigating diminished ovarian reserve and highlight advances in biomimetic nanotechnology for reproductive medicine.

• MHY1485: mTOR Activator Transforming Autophagy and Ovarian R

  2026-05-11

  MHY1485 stands out as a potent mTOR activator uniquely enabling simultaneous control over autophagy inhibition and ovarian follicle development in translational research. With optimized solubility and robust pathway modulation, it empowers reproducible workflows in cell metabolism, disease modeling, and reproductive biology.

• Erastin and the Execution of Ferroptosis: New Insights for C

  2026-05-10

  Explore the advanced role of Erastin as a ferroptosis inducer in cancer research. This article uniquely dissects late-stage ferroptotic mechanisms and practical assay implications for targeting tumor vulnerabilities.

• Syringin Enhances Sunitinib Efficacy via EGFR/PI3K/Akt in RC

  2026-05-09

  This study demonstrates that Syringin, a plant-derived phenylpropanoid glycoside, inhibits renal cell carcinoma (RCC) cell proliferation and enhances apoptosis by targeting the EGFR/PI3K/Akt signaling pathway. Notably, Syringin significantly increases RCC sensitivity to sunitinib, suggesting a mechanistically validated strategy to overcome drug resistance in RCC treatment.

• Pharmacological SMYD2 Inhibition Attenuates Cisplatin-Induce

  2026-05-09

  This study demonstrates that pharmacological inhibition of SMYD2, particularly with AZ505, mitigates cisplatin-induced renal fibrosis and inflammation by modulating key fibrotic and inflammatory signaling pathways. The findings highlight SMYD2 as a promising epigenetic target in chronic kidney disease (CKD) models and provide mechanistic insight for translational research using selective SMYD2 inhibitors.

• BAPTA-AM: Cell-Permeable Calcium Chelator for Precision Assa

  2026-05-08

  BAPTA-AM empowers researchers to dissect calcium signaling with unmatched spatial and temporal precision, enabling advanced live-cell imaging, apoptosis, and neuroprotection workflows. Leveraging its dual role as a calcium chelator and potassium channel blocker, BAPTA-AM stands out for experimental flexibility and reproducibility in complex cellular systems.

• METTL14-Mediated m6A Modification in Ulcerative Colitis Infl

  2026-05-07

  This study elucidates how METTL14, by modulating m6A methylation on the lncRNA DHRS4-AS1, regulates inflammatory responses in ulcerative colitis via the DHRS4-AS1/miR-206/A3AR axis. The findings highlight a mechanistic link between epigenetic RNA modification and intestinal inflammation, presenting new avenues for targeted research in inflammatory bowel disease.

• Erastin: Benchmark Ferroptosis Inducer for Oncology Research

  2026-05-07

  Erastin is a validated small molecule ferroptosis inducer that selectively triggers iron-dependent, non-apoptotic cell death in tumor cells with RAS or BRAF mutations. APExBIO’s Erastin (B1524) is widely used in cancer biology research to dissect oxidative stress pathways. This article provides structured, evidence-backed insights into Erastin’s mechanism, applications, and limitations.

16908 records 5/1128 page Previous Next 12345 下5页 Last page